CRISPR — short for clustered regularly interspaced short palindromic repeats — is a method of genetic editing that uses RNA ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

Tulane University researchers have developed an enhanced CRISPR-based tuberculosis test that works with a simple tongue swab, ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced ...

Horses with genomic edits to make them run faster have been banned from polo, but a zoo of CRISPR-edited animals is gaining ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Researchers engineered and screened dozens of base editors to precisely target a single mutation without editing other portions of the DNA.

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

The evolutionary blueprint for hands was borrowed in part from a much older genetic plan for our nether regions, a new study ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $59.07, moving -3.46% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.1%.